The story so far:
Tissue Regenix, based at York Science Park, made the announcement about its woundcare product DermaPure, which works by using the firm’s dCELL technology to utilise human and animal tissues to create scaffolds to repair body parts by removing the DNA and cells.
The product is primarily aimed at the treatment of chronic wounds associated with diabetes, which affects around 10 per cent of the American population, making the prevalence of hard to heal wounds, a common side effect of the disease, increase rapidly.
In addition, DermaPure is being used in a number of other varied clinical settings, treating conditions from pressure ulcers to frostbite. It is expected that Tissue Regenix will now develop this same dCELL technology into products addressing other applications.
Greg Bila, president of Tissue Regenix Woundcare, Inc. said: “Since launch in 2014, the uptake of DermaPure within a competitive marketplace has been highly encouraging and we are thrilled to announce the first $1 million of sales.
“We are finding that it is the intrinsic qualities of DermaPure which make it effective and differentiate it from other products available.
“Unlike cell based products, DermaPure signals the body to redirect the patient’s own cells to the affected area, allowing the body to regenerate healthy tissue.
“I would like to thank our clinical affairs and sales teams, whose hard work has allowed us to reach this milestone, and look forward to seeing continued momentum in the coming year.”
"Since launch in 2014, the uptake of DermaPure within a competitive marketplace has been highly encouraging and we are thrilled to announce the first $1 million of sales." Greg Bila - President of Tissue Regenix Woundcare, Inc.